Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02746393 · ClinicalTrials.gov registry record · NA
SFGH Health Advocates Stage II Study
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 1,278
- Enrollment target
NCT02746393: Completed NA study, sponsored by University of California, San Francisco.
NCT02746393 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 1,278 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02746393, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,278 participants
- Enrollment target
Study Summary
The San Francisco General Hospital (SFGH) Health Advocate Staff II Study is a Randomized Controlled Trial (RCT) that collects survey data and non-invasive biological data from caregivers and children visiting a pediatric urgent care center. Families will be randomized according to a pre-determined randomization schedule into one of two social needs-focused interventions (the Health Advocates Program or a 211 Information active comparator arm). All patients in the study will be followed over a six month period to capture information about changes in social needs, health and health care utilization.
Primary Outcome
Collected at baseline and 6 month follow up
Interventions
- OTHER Health Advocates Program
- OTHER 211 Information Sheet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,278 participants |
| Start Date | 2016-07 |
| Est. Completion | 2020-07 |
| Phase | NA |
What the finished NCT02746393 record still lists
NCT02746393 is an interventional study that assigns participants to a tested intervention. Its 1,278 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Health Advocates Program is the first listed.
NCT02746393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02746393 about?
NCT02746393 is a clinical study titled "SFGH Health Advocates Stage II Study". The San Francisco General Hospital (SFGH) Health Advocate Staff II Study is a Randomized Controlled Trial (RCT) that collects survey data and non-invasive biological data from caregivers and children visiting a pediatric urgent care center. Families will be randomized according to a pre-determined r...
What is the current status of trial NCT02746393?
This trial is currently completed. It is a NA study. The enrollment target is 1,278 participants. The study started on 2016-07. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02746393?
The interventions under investigation include: Health Advocates Program (OTHER), 211 Information Sheet (OTHER).
Who is sponsoring clinical trial NCT02746393?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02746393's enrollment target sits among peer trials
1,278 78th of 2000 higher than 1,923 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia